Third-Party Audit Services for Pharmaceutical & Biotech Manufacturers
Are Your Third-Party Audits Truly Protecting Your Organization or Simply Checking a Box? In the complex Life sciences ecosystem, Third-party audits are critical for supplier oversight, contract manufacturers, and laboratory operations. Yet even experienced companies can face unexpected regulatory setbacks. Case in Point: A global Biotech manufacturer had relied on multiple external auditors over the years. All audits returned “acceptable” results. However, […]
Life Sciences Audits: Comprehensive Compliance Support by BioBoston Consulting
Are Your Audits Truly Strengthening Compliance or Leaving Critical Gaps Unseen? Across Pharmaceutical, Biotech, and Medical device sectors, companies routinely conduct internal and supplier audits. Yet, many still face unexpected compliance issues, regulatory citations, and supply chain disruptions. Why? Because not all audits are deep enough to uncover systemic risks that can impact product quality, data integrity, and regulatory compliance. Real-World Example: A Mid-sized Biotech company’s audits […]
Is Your Organization Truly Ready for an FDA Audit?
For Biotech, Pharmaceutical, and Medical device companies, FDA inspections are high-stakes events. Many organizations that believe they are inspection ready are caught off guard when auditors uncover systemic issues, data integrity gaps, or supplier failures that internal audits missed. Real-World Example: A Mid-sized Biopharma company had passed multiple internal audits with “no critical issues noted.” Yet during a pre-approval FDA inspection, investigators identified: Incomplete CAPA […]
Audit Readiness Programs for FDA, EMA, and Global Regulatory Bodies
Regulatory inspections are a critical milestone for Biopharma, Pharmaceutical, and Medical device companies. Yet many organizations that believe they are ready for an FDA, EMA, or global regulatory audit are often surprised by hidden gaps in compliance, data integrity, or operational oversight. Case in point: A mid-sized Biotech company completed multiple internal and supplier audits but faced unexpected findings during an FDA […]
Are Your GMP, GLP & GCP Audits Truly Protecting Your Organization or Leaving Hidden Gaps Behind?
In today’s regulatory environment, Biotech and Pharmaceutical companies must maintain GMP compliance, GLP integrity, and GCP adherence across their entire value chain from manufacturing to laboratories to clinical trials. Yet, even with regular internal and supplier audits, companies can be caught off guard during FDA, EMA, or MHRA inspections. A recent example: A Pharmaceutical company believed their GMP audits ensured compliance. During […]
Are Your Supplier & Internal Audits Truly End-to-End or Are Critical Risks Still Slipping Through?
Life sciences companies across Biotech, Pharmaceutical, and Medical device sectors rely on a complex ecosystem of suppliers, CMOs, testing labs, raw material vendors, and internal quality systems. Yet even with regular supplier and internal audits, many organizations face regulatory surprises. Real-World Example: A Biotech company conducted multiple audits throughout the year, all appearing compliant on paper. During an FDA inspection, investigators found: Documentation […]
Are Your Internal and Supplier Audits Truly Helping You or Hiding Critical Risks?
Are Your Audits Truly Strengthening Compliance or Leaving Critical Gaps Unseen? Across Pharmaceutical, Biotech, and Medical device sectors, companies routinely conduct internal and supplier audits. Yet, many still face unexpected compliance issues, regulatory citations, and supply chain disruptions. Why? Because not all audits are deep enough to uncover systemic risks that can impact product quality, data integrity, and regulatory compliance. Real-World Example: A Mid-sized Biotech company’s audits […]
Are Your Quality System Audits Truly Ensuring Compliance or Allowing Critical Gaps to Go Unnoticed?
Not long ago, a mid-sized pharmaceutical company faced an unexpected crisis. Despite recent internal and supplier audits reporting “no critical findings,” an FDA inspection revealed major data integrity failures at one of their raw material suppliers. Equipment qualification records were incomplete, electronic audit trail reviews were inconsistent, and change controls were documented retroactively. The impact […]